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The porphyrias are disorders of the heme biosynthetic pathway. Heme is a very 
important prosthetic group of several human and mammalian proteins, including 
hemoglobin, myoglobin, cytochromes, catalases and peroxidases. That’s why it is 
synthesized not only in the bone marrow (75-80 % of the whole) but also in the liver 
(15-20%), muscles and other organs.1
Heme is a tetrapyrrole, e.g. a molecule consisting of four pyrrole rings bound via 
methine bridges and linked in cyclic fashion. The cyclic tetrapyrroles can chelate sev-
eral metal ions forming biological pigments of major importance –such as heme (with 
iron), chlorophyll (with magnesium) or cobalamin (with cobalt). In humans, heme is 
synthesized through a complex biosynthetic procedure involving eight enzymes. The 
initial step takes place in the mitochondria, where the amino acid glycine reacts with 
succinic acid to form δ-aminolevulinic acid (ALA), the first intermediate product 
of this metabolic pathway. This reaction is catalyzed by the enzyme ALA-synthase 
(ALA-S). The biosynthetic procedure is then transformed to the cytoplasm, where two 
molecules of ALA are condensed to form a pyrrole, porphobilinogen (PBG). Through 
the concurrent action of two different enzymes, four molecules of PBG form the first 
tetrapyrrole molecule, uroporphyrinogen. In the following steps, the side chains of 
the tetrapyrrole undergo several changes passing through coproporphyrinogen and 
protoporphyrinogen to finally form protoporphyrin. An atom of iron is incorporated 
to the protoporphyrin and so heme is produced. All these steps are catalyzed by four 
additional enzymes, the last three of them being present in mitochondria. So, the 
biosynthetic procedure begins and ends in mitochondria, with an interlude occurring 
in the cytoplasm.2
It must be here emphasized that heme biosynthesis in the liver -but not in the 
bone marrow- is regulated through a negative feed-back mechanism involving the 
final product, heme. Heme inhibits the synthesis of ALA-S, which is the first and 
rate-limiting enzyme of the metabolic pathway. When heme is in abundance in the 
hepatic cell, ALA-S synthesis is decreased and the whole procedure runs slower. When 
liver heme is depleted, we have the opposite result. Hepatic ALA-S synthesis is also 
downregulated by excess of glucose (glucose effect). These mechanisms are of major 
importance in the pathogenesis of the attacks of acute porphyria.
The first medical description of a case of porphyria was made in 1889 by Barent 
Stokvis, a Dutch professor of Medicine. King George III of England3, the poet Hein-
rich Heine and the painter Vincent van Gogh were possibly suffering of some type 
of porphyria. All porphyrias are inherited disorders due to gene mutations, with the 
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exception of porphyria cutanea tarda –the most common type 
of cutaneous porphyrias– which is an acquired disease. The 
underlying biochemical defectisdecreased activity of one the 
last seven enzymes (from the 2nd to the 8th) involved in heme 
biosynthesis. According to whether the disorder mainly affects 
heme synthesis in the bone marrow or the liver, the disease 
is classified as erythropoietic or hepatic porphyria. There are 
several types of hepatic porphyria –according to the affected 
enzyme– which differ in their clinical manifestations. Some 
of them present with acute attacks of several neurologic 
symptoms while in the intermediate periods –more or less 
prolonged– the patient is asymptomatic. These are called acute 
porphyrias. In the other types –as well as in all the erythropoi-
etic porphyrias– the patient has only cutaneous manifestations 
with periodic exacerbations. These are called non-acute or 
cutaneous porphyrias.
The gene mutation is a necessary prerequisite, but not per 
se sufficient for the clinical manifestation of acute porphyria. 
Among the mutation carriers, 1 in 3 has abnormal laboratory 
findings and only 1 in 5-10 is symptomatic. The underlying 
decreased activity of one enzyme results in decreased produc-
tion of hepatic heme. So, ALA-S synthesis is induced through 
the negative feed-back mechanism. Increased ALA-S activity 
results in overproduction of intermediate products prior to 
the defective enzyme. The heme precursors are useless but 
harmless in normal concentrations and they are excreted, ac-
cording to their water solubility, by the urine or feces. However, 
in increased concentrations they become toxic either for the 
nervous system (mainly ALA and possibly PBG) or the skin 
(uro-, copro, and proto-porphyrin). This explains why the 
clinical manifestations of porphyrias are neurologic and/or 
cutaneous.  For example, if the defective enzyme is the 3rd one 
–as happens in acute intermittent porphyria, the most common 
type of acute porphyria– ALA and PBG are overproduced 
and accumulated and the patient has only neurologic symp-
toms. Defects of some of the subsequent enzymes may cause 
overproduction of neurotoxic intermediates and porphyrins 
and so the patient may have both neurologic and cutaneous 
manifestations of porphyria.
Attacks of acute porphyria usually occur between the 2nd 
and 4th decades of life, tending to become rarer or disappear 
with increasing age. Menopause or development of diabetes 
mellitus4 are two possible explanations for this phenomenon. 
Abdominal pain is the most usual clinical manifestation. It 
is constant, severe, imitating acute abdomen, although not 
actually accompanied by peritonism. Vomiting, tachycardia 
and hypertension usually coexist, while constipation is often 
persisting during the whole period of the attack. All these 
manifestations are not related to any visceral pathology but 
only to autonomic neuropathy. Hyponatremia due to inad-
equate antidiuretic hormone secretion is a common finding 
and may be severe. In a considerable proportion of patients, 
acute visceral symptoms may progress to motor neuropathy 
presenting mainly as weakness of the proximal limb muscles. In 
a few cases, neuropathy also involves the respiratory muscles, 
becoming life-threatening. Sensory changes and seizures may 
be additional features of the porphyric attack. In two less com-
mon types of acute porphyria (variegate porphyria, hereditary 
coproporphyria) skin lesions with marked photosensitivity 
may also coexist.
There are several precipitating factors of acute attacks. 
The most common are prolonged starvation or marked re-
duction of carbohydrate intake, administration of drugs that 
either directly induce ALA-S or decrease hepatic heme by 
increasing liver cytochromes synthesis, over secretion of female 
hormones –especially progesterone, as in the luteal phase of 
the menstrual cycle or in pregnancy–, cigarette smoking and 
stress induced by infection, surgery or psychological factors. 
However, sometimes attacks occur without a recognizable 
triggering factor.5
Acute porphyria is generally considered as a succession 
of crises with complete resolution of symptoms among them. 
However, during the last decades it is recognized that acute 
porphyria may also have chronic complications. Persisting 
chronic pain due to an axonal motor polyneuropathy may ap-
pear, especially in patients with multiple recurrent attacks. In 
some cases, it is so severe that leads to depression and anxiety 
or even suicide attempts. Chronic renal disease of the type 
of chronic tubulo-interstitial nephropathy or focal cortical 
atrophy (possibly attributed to ALA nephrotoxicity), mental 
disorders (hysteria or neurosis) and chronic hypertension are 
other known chronic complications. Furthermore, the risk 
of hepatocellular cancer is considerably higher than in the 
general population.1
Management of acute attacks is both symptomatic and 
etiologic. Relief of pain and the other symptoms is limited by 
the fact that several common drugs are considered “unsafe”. 
For example, most non-steroid anti-inflammatory agents are 
contraindicated and the pain must be mainly relieved by the use 
of opiates. The only available means of etiologic treatment aim 
at decreasing ALA-S activity. High carbohydrate intake –either 
per os or through intravenous administration of hypertonic 
(20%) glucose solutions– is recommended, taking advantage 
of the aforementioned glucose effect. Administration of heme, 
direct inhibitor of hepatic ALA-S, is the other therapeutic ap-
proach. Several heme formulations have proved problematic 
until hemin arginate was introduced. This is considerably 
effective –if administered early– and with minor side-effects, 
but it is not always available due to high cost and limited use.6
Prevention of acute attacks is mainly achieved by avoidance 
of triggering factors. A well-balanced diet with carbohydrates 
covering 60-70 % of total calories is indicated. Gonadotropin-
releasing hormone analogues can prove useful in women by 
preventing monthly recurrent attacks related to their menstrual 
cycle. A prophylactic intravenous heminarginate administra-
tion (1-2 weekly) has proved useful in some patients that 
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could not otherwise behelped.1 However, all these measures 
have often been difficult to apply or ineffective. Furthermore, 
some patients with repeated attacks of pain are prone to opi-
ate dependence.
The introduction of small interfering RNA molecules 
(siRNAs) seems to be a revolutionary innovation in modern 
therapeutics. siRNA is a small (20-30 nucleotides) noncoding-
synthetic double-stranded RNA designed to specifically target 
a particular mRNA. Its binding results in mRNA cleavage 
and degradation. So, siRNAs have currently been introduced 
in clinical practice in order to selectively target and suppress 
disease-causing genes. Current investigation focuses on several 
applications of them in cardiovascular diseases, neurological 
disorders, or malignancies.7
It is interesting that the whole story originated from an at-
tempt to change the color of a common flower, petunia. Napoli 
et al reported in 1990 that they attempted to overexpress an 
enzyme responsible for the production of anthocyanin, the 
pigment of violet petunias by introducing a chimeric gene. 
Despite their expectations, the introduced gene created a block 
in anthocyanin biosynthesis.8 That was the first indication that 
introduction of a nucleic acid in cells could block protein syn-
thesis. In 1998 Fire and Mello reported that introduction of a 
double-stranded RNA was substantially more effective at pro-
ducing interference in the nematode Caenorhabditis elegans 
than was either strand individually.9 This phenomenon was 
called RNA inhibition and offered them a Nobel prize in 2006. 
A new agent for the prevention of porphyric attacks has 
recently been approved by the u.S. food and drug Admin-
istration (2019) and the European Medicines Agency (2020) 
under the generic name of givosiran. Givosiran is an siRNA 
molecule that can selectively bind to the m-RNA for ALA-S.
It enters the hepatocytes by binding to the acialglycoprotein 
receptor of the cell membrane. Entering the cell, it is directed 
to the ribosomes where it rejects its complementary strand 
and binds to a molecule of the ALA-S mRNA. This binding 
resultsin degradation of the latter. Through this mechanism, 
ALA-S production is considerably decreased.
A phase 1 clinical trial showed that patients with acute 
porphyria receiving givosiran had a sustainable decrease of 
ALA-S mRNA and urinary ALA and PBG to near normal 
levels.10 Subsequently, a double-blind phase 3 clinical trial 
(ENVISION) was performed. Givosiran (2.5 mg/kg b.w.) or 
placebo was subcutaneously administered in 94 symptomatic 
patients with acute hepatic porphyria once per month for 6 
months. The mean annualized attack rate was 74% lower in the 
givosiran than in the placebo group (3.2 versus 12.5, p<0.001). 
Patients receiving givosiran also had significantly lower levels 
of urinary ALA and PBG, fewer days of hemin use, and better 
pain daily scores if suffering of chronic neuropathic pain. After 
completion of the 6-months period, the patients in the placebo 
group also passed to givosiran and had similar responses 
concerning urinary ALA and PBG and attack rate. The effect 
remained constant with the passing of time. The safety profile 
of givosiran was good enough with minor and usually reversible 
elevations of serum creatinine and aminotransferases as well 
as mild or moderate injection-site reactions. Hepatic heme 
content or heme-dependent enzyme activities were not strongly 
affected by the administration of givosiran.11
So, intervention with a specific siRNA molecule seems to 
be an effective way to prevent attacks in patients with acute 
hepatic porphyrias. This treatment is expected to greatly im-
prove the quality of life of these patients and also save the cost 
for their hospitalization or drug treatment. However, there 
are some questions that remain unanswered. Will the effect 
of givosiran persist over more prolonged time-periods? May 
its prolonged use and ALA-S inhibition be accompanied by 
other side-effects? And more, important: may this treatment 
also ameliorate the chronic complications of porphyria, such 
as renal damage, psychiatric disorders or liver cancer? These 
are questions that may only be answered through the long-term 
use of givosiran or similar drugs.
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